Avastin found effective in advanced breast cancer patients
Avado Study of Avastin Plus Docetaxel Chemotherapy Showed Improved Progression-Free Survival in Patients With Advanced Breast Cancer – Genentech, Inc. (NYSE: DNA) announced that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin? (bevacizumab) in combination with docetaxel chemotherapy met its primary endpoint of prolonging progression-free survival (PFS) in patients who had not received prior chemotherapy for their locally recurrent or metastatic HER2-negative breast cancer.